CONCOMITANT AUTOLOGOUS CHONDROCYTE IMPLANTATION AND MENISCUS ALLOGRAFT OR SYNTHETIC MENISCUS SCAFFOLD TRANSPLANTATION AT MID-TERM FOLLOW-UP

Jingsong Wang; Sally Roberts; Helen McCarthy; Bernhards Tins; Pete Gallacher; James Richardson; Karina Wright

doi:10.1302/1358-992X.2021.2.077

Article alerts Social media

Current issue

Research

CONCOMITANT AUTOLOGOUS CHONDROCYTE IMPLANTATION AND MENISCUS ALLOGRAFT OR SYNTHETIC MENISCUS SCAFFOLD TRANSPLANTATION AT MID-TERM FOLLOW-UP

The British Orthopaedic Research Society (BORS) Annual Meeting 2020, held online, 7–8 September 2020.

Jingsong Wang
Sally Roberts
Helen McCarthy
Bernhards Tins
Pete Gallacher
James Richardson
Karina Wright

CONCOMITANT AUTOLOGOUS CHONDROCYTE IMPLANTATION AND MENISCUS ALLOGRAFT OR SYNTHETIC MENISCUS SCAFFOLD TRANSPLANTATION AT MID-TERM FOLLOW-UP

Wang J, Roberts S, McCarthy H, et al. CONCOMITANT AUTOLOGOUS CHONDROCYTE IMPLANTATION AND MENISCUS ALLOGRAFT OR SYNTHETIC MENISCUS SCAFFOLD TRANSPLANTATION AT MID-TERM FOLLOW-UP. Orthop Procs. 2021;103-B(SUPP_2):77-77. doi:10.1302/1358-992X.2021.2.077

Wang, Jingsong, et al. “CONCOMITANT AUTOLOGOUS CHONDROCYTE IMPLANTATION AND MENISCUS ALLOGRAFT OR SYNTHETIC MENISCUS SCAFFOLD TRANSPLANTATION AT MID-TERM FOLLOW-UP.” Orthopaedic Proceedings, vol. 103-B, no. SUPP_2, 2021, pp. 77-77., https://doi.org/10.1302/1358-992X.2021.2.077

Wang, J., Roberts, S., McCarthy, H., Tins, B., Gallacher, P., Richardson, J., & Wright, K. (2021). CONCOMITANT AUTOLOGOUS CHONDROCYTE IMPLANTATION AND MENISCUS ALLOGRAFT OR SYNTHETIC MENISCUS SCAFFOLD TRANSPLANTATION AT MID-TERM FOLLOW-UP. Orthopaedic Proceedings, 103-B(SUPP_2), 77-77. https://doi.org/10.1302/1358-992X.2021.2.077

Wang, J., Roberts, S., McCarthy, H., Tins, B., Gallacher, P., Richardson, J. et al. (2021) “CONCOMITANT AUTOLOGOUS CHONDROCYTE IMPLANTATION AND MENISCUS ALLOGRAFT OR SYNTHETIC MENISCUS SCAFFOLD TRANSPLANTATION AT MID-TERM FOLLOW-UP.” Orthopaedic Proceedings, 103-B(SUPP_2), pp. 77-77. Available at: https://doi.org/10.1302/1358-992X.2021.2.077

Wang, Jingsong, Sally Roberts, Helen McCarthy, Bernhards Tins, Pete Gallacher, James Richardson, and Karina Wright. “CONCOMITANT AUTOLOGOUS CHONDROCYTE IMPLANTATION AND MENISCUS ALLOGRAFT OR SYNTHETIC MENISCUS SCAFFOLD TRANSPLANTATION AT MID-TERM FOLLOW-UP.” Orthopaedic Proceedings 103-B, no. SUPP_2 (2021): 77-77. https://doi.org/10.1302/1358-992X.2021.2.077

Wang J, Roberts S, McCarthy H, Tins B, Gallacher P, Richardson J, et al. CONCOMITANT AUTOLOGOUS CHONDROCYTE IMPLANTATION AND MENISCUS ALLOGRAFT OR SYNTHETIC MENISCUS SCAFFOLD TRANSPLANTATION AT MID-TERM FOLLOW-UP. Orthop Procs. 2021 Mar 1;103-B(SUPP_2):77-77. https://doi.org/10.1302/1358-992X.2021.2.077

Copy to clipboard

BibTeX

EndNote

RIS

Abstract

Objectives

Meniscus allograft and synthetic meniscus scaffold (Actifit^®) transplantation have shown promising outcomes for symptoms relief in patients with meniscus deficient knees. Untreated chondral defects can place excessive load onto meniscus transplants and cause early graft failure. We hypothesised that combined ACI and allograft or synthetic meniscus replacement might provide a solution for meniscus deficient individuals with co-existing lesions in cartilage and meniscus.

Methods

We retrospectively collected data from 17 patients (16M, 1F, aged 40±9.26) who had ACI and meniscus allograft transplant (MAT), 8 patients (7M, 1F, aged 42±11) who underwent ACI and Actifit^® meniscus scaffold replacement. Other baseline data included BMI, pre-operative procedures and cellular transplant data. Patients were assessed by pre-operative, one-year and last follow-up Lysholm score, one-year repair site biopsy, MRI evaluations.

Results

In the MAT group, the final post-operative evaluation was 7±4.5 years. The mean pre-operative Lysholm score was 49±17, rose to 66.6±16.4 1 year post-op and dropped to 58±26 at final evaluation. Four of the 17 patients had total knee replacements (TKRs) at average 6.4 years after treatment. In the Actifit^® group, the final post-operative assessment was 5.6±2.7years. The pre-operative Lysholm score was 53.7±21.3, increasing to 72.8±15.2 at 1 year and 70.4±27.6 at final clinical follow-up. None of the patients in the Actifit® group had received TKRs.

Conclusions

Both MAT and Actifit^® groups were effective in improving patients symptoms and knee function according to one-year post-operative assessments. However, the knee function of patients in MAT group dropped at final follow-up, whereas the Actifit® group maintained their knee function. These preliminary findings warrant further investigations, to include more patients and alongside comparisons to ACI alone and allograft/Actifit^® alone as comparator groups before accurate conclusions may be drawn on the comparative efficacy of each technique.

Declaration of Interest

(b) declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported:I declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research project.